sábado, 16 de julio de 2022

Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City - The Lancet Rheumatology

Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City - The Lancet Rheumatology

No hay comentarios:

Publicar un comentario